Impact of the timing of hepatitis B virus (HBV) identification and anti-HBV therapy initiation on the risk of adverse liver outcomes in patients receiving cancer therapy

BACKGROUND: Data on incidence of adverse liver outcomes is limited for cancer patients with chronic (HBsAg+/anti-HBc+) or past (HBsAg−/anti-HBc+) hepatitis B virus (HBV) after chemotherapy. We aimed to determine the impact of test timing and anti-HBV therapy on adverse liver outcomes in these patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer
Hauptverfasser: Hwang, Jessica P., Suarez-Almazor, Maria E., Cantor, Scott B., Barbo, Andrea, Lin, Heather Y., Ahmed, Sairah, Chavez-MacGregor, Mariana, Donato-Santana, Christian, Eng, Cathy, Ferrajoli, Alessandra, Fisch, Michael J., McLaughlin, Peter, Simon, George R., Rondon, Gabriela, Shpall, Elizabeth J., Lok, Anna S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568919/
https://ncbi.nlm.nih.gov/pubmed/28518219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30729
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge